Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane (PanCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03003078
Recruitment Status : Completed
First Posted : December 26, 2016
Last Update Posted : July 13, 2021
Sponsor:
Information provided by (Responsible Party):
OncoSil Medical Limited

Tracking Information
First Submitted Date  ICMJE December 20, 2016
First Posted Date  ICMJE December 26, 2016
Last Update Posted Date July 13, 2021
Actual Study Start Date  ICMJE March 27, 2017
Actual Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 6, 2017)
Safety / Tolerability of Device according to CTCAE V4.0 [ Time Frame: Collected from the of signed informed consent until patient death or 104 weeks post last patient enrollment date, whichever is sooner ]
as determined by the number of treatment emergent adverse events (TEAEs) evaluated
Original Primary Outcome Measures  ICMJE
 (submitted: December 21, 2016)
Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0 [ Time Frame: Collected from the of signed informed consent until patient death or 104 weeks post last patient enrollment date, whichever is sooner ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 6, 2017)
  • Local Progression free survival within the pancreas [ Time Frame: Assessed from Baseline through to first confirmed CT documentation of local progression within the pancreas, an average of 12 months. ]
    Central reader review of CT changes throughout study enrolment
  • Progression free survival - entire body [ Time Frame: Assessed from Baseline through to EOS visit - an average of 12 months. ]
    Central reader review of CT changes throughout study enrolment
  • Overall survival [ Time Frame: 104 weeks post last patient first study visit ]
    Time to participant death from enrolment
  • Body weight [ Time Frame: Assessed from Baseline through to EOS visit, an average of 12 months. ]
    Recorded body weight at each study visit
  • Impaired function [ Time Frame: Frame: Measured at each study visit for the duration of the study, an average of 12 months ]
    as measured by changes in the Karnofsky Performance Status from screening
  • Pain Scores [ Time Frame: Measured at each study visit for the duration of the study, an average of 12 months ]
    As measured at each study visit using the Numerical Rating scale (NRS)
Original Secondary Outcome Measures  ICMJE
 (submitted: December 21, 2016)
  • Local Progression free survival within the pancreas [ Time Frame: Assessed from Baseline through to first confirmed CT documentation of local progression within the pancreas, an average of 12 months. ]
  • Progression free survival - entire body [ Time Frame: Assessed from Baseline through to EOS visit - an average of 12 months. ]
  • Overall survival [ Time Frame: 104 weeks post last patient first study visit ]
  • Body weight [ Time Frame: Assessed from Baseline through to EOS visit, an average of 12 months. ]
  • Impaired function as measured by changes in the Karnofsky Performance Status from screening [ Time Frame: Frame: Measured at each study visit for the duration of the study, an average of 12 months ]
  • Pain Scores [ Time Frame: Measured at each study visit for the duration of the study, an average of 12 months ]
Current Other Pre-specified Outcome Measures
 (submitted: March 6, 2017)
  • tumour response [ Time Frame: Baseline measure from screening period, compared to Week 8 CT result, and then to 8 weekly CT results until local progression is determined, an average of 12 months. ]
    as demonstrated by target tumour volumetric change (measured by a central reading centre)
  • tumour response [ Time Frame: As assessed at Week 12 study visit compared to Baseline assessment completed during screening period ]
    as demonstrated by target tumour FDG-PET parameters (measured by a central reading centre)
Original Other Pre-specified Outcome Measures
 (submitted: December 21, 2016)
  • tumour response as demonstrated by target tumour volumetric change (measured by a central reading centre) [ Time Frame: Baseline measure from screening period, compared to Week 8 CT result, and then to 8 weekly CT results until local progression is determined, an average of 12 months. ]
  • tumour response as demonstrated by target tumour FDG-PET parameters (measured by a central reading centre) [ Time Frame: As assessed at Week 12 study visit compared to Baseline assessment completed during screening period ]
 
Descriptive Information
Brief Title  ICMJE A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane
Official Title  ICMJE An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies
Brief Summary

To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy regulatory requirements.

The clinical investigation will be conducted at approximately 15 sites in Australia, the United Kingdom and Europe (Belgium) involving 40 patients.

Detailed Description

Detailed description

The purpose of this research study is to investigate the safety of an active implantable (radiological) medical device OncoSil™, when implanted into patients with pancreatic cancer, in conjunction with Standard of Care (SOC) chemotherapy. OncoSil™, is an experimental treatment and carries the active treatment "radioactive Phosphorous (32P)" inside inactive silicon particles. Once implanted, the OncoSil™ Microparticles will stay in the tumour permanently. The purpose of OncoSil™, is to deliver the action of 32P directly into a targeted tumour to destroy cancer cells.

40 Patients will be taking part in a single arm open label research study - which means that everyone in the research study will receive the investigational treatment OncoSil™, plus their prescribed standard chemotherapy regimen which will be either; FOLFIRINOX (FOLFIRINOX is the name of a combination of chemotherapy drugs used to treat advanced cancer of the pancreas) or gemcitabine + nab-paclitaxel (Abraxane).

Endpoints: Primary Endpoint:

• Safety and Tolerability

Secondary Endpoints:

Efficacy

  • Local Disease Control Rate at 16 weeks
  • Local Progression Free Survival (LPFS), within the pancreas
  • Progression Free Survival (PFS), all sites
  • Overall Survival (OS)
  • Body weight
  • Impaired function
  • Pain Scores

The screening period will be performed within a 2 week period, followed by a treatment period of investigational visits which will occur weekly from Day 0 (Visit 1) until week 12, then 4 weeks later at week 16, and then at 8-weekly intervals until study participants reach documented progression of disease criteria for both LPFS and PFS which marks the end of study participation i.e. EOS visit.

An 8-weekly review of medical records will be used to monitor possible device or late radiation related adverse events, and oncology treatments/procedures administered for up to 12 months post OncoSil™ implantation.

Overall survival will be conducted via 8-weekly medical record reviews until study participant death, or until 104 weeks post the last study participant enrolled.

Activity (Dose): The intended average absorbed radiation dose per treated tumour is 100 Gy (+20%).

Risks associated with OncoSil™ and/or implantation procedure

The following adverse events, considered to have a causal relationship with OncoSil™ or procedure, were recorded during previous clinical studies:

  • Procedure-related pain
  • Abdominal pain and discomfort
  • Lethargy
  • Fever
  • Nausea and vomiting
  • Abnormal liver function tests
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Unresectable Locally Advanced Pancreatic Carcinoma
Intervention  ICMJE Device: OncoSil™
The implantation of OncoSil™
Study Arms  ICMJE OncoSil™ plus SOC Chemotherapy
OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
Intervention: Device: OncoSil™
Publications * Naidu J, Bartholomeusz D, Zobel J, Safaeian R, Hsieh W, Crouch B, Ho K, Calnan D, Singhal N, Ruszkiewicz A, Chen JW, Tan CP, Dolan P, Nguyen NQ. Combined chemotherapy and endoscopic ultrasound-guided intratumoral 32P implantation for locally advanced pancreatic adenocarcinoma: a pilot study. Endoscopy. 2021 Jan 13. doi: 10.1055/a-1353-0941. [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 17, 2018)
50
Original Estimated Enrollment  ICMJE
 (submitted: December 21, 2016)
20
Actual Study Completion Date  ICMJE July 31, 2020
Actual Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically or cytologically proven adenocarcinoma of the pancreas.
  2. Unresectable locally advanced pancreatic carcinoma. Patients with technically resectable tumours (T1-T3) will also be eligible, if they are deemed unresectable due to medical comorbidities or refusal of surgery.
  3. Pancreatic target tumour diameter of ≥ 2.0 cm (shortest axis) to ≤ 6.0 cm (longest axis), as qualified by the central reading centre.
  4. An ECOG Performance Status of 0 to 1 and Karnofsky Performance Status of 80 - 100.
  5. Study participants ≥ 18 years of age at screening.
  6. To commence first-line standard FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapy (per standard of care according to the approved prescribing schedule), within 14 days post enrolment, with OncoSil™ implantation to occur during the fourth (4th) week of the first chemotherapy cycle.
  7. Provide signed Informed Consent.
  8. Willing and able to complete study procedures within the study timelines.
  9. Adequate renal function: serum creatinine less than 1.5 x upper limit of normal (ULN).
  10. Adequate liver function: serum liver transaminases ≤ 3 × ULN and serum bilirubin

    ≤ 1.5 × ULN*.

    *For study participants with recent biliary obstruction treated by drainage (e.g. stent), serum bilirubin of > 1.5 x ULN will be accepted for study entry provided that serial levels demonstrate clear improvement. In addition, chemotherapy should not be commenced until serum bilirubin is ≤ 1.5 × ULN.

  11. Adequate bone marrow function: white blood cells (WBCs) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, haemoglobin ≥ 9 g/dL, and platelets ≥ 100,000/mm3.
  12. Life expectancy of at least 3 months at the time of screening as judged by the investigator.
  13. Treated with or eligible to commence prophylactic treatment with a proton-pump inhibitor prior to implantation, and to continue to receive treatment for at least 6 months post implantation.
  14. Not pregnant, and if of childbearing potential, agrees to use adequate birth control (hormonal or barrier method of birth control or abstinence) prior to study entry and during the study and agrees not to donate sperm or ova, for the duration of the study and 12 months post implantation of the investigational device.

Exclusion Criteria

  1. Evidence of distant metastases, based on review of baseline CT scan, as determined by the central reading centre.
  2. More than one primary lesion.
  3. Any prior radiotherapy or chemotherapy for pancreatic cancer.
  4. Use of other investigational agent at the time of screening, or within 30 days or five half-lives of Screening Visit 1, whichever is longer.
  5. Pregnant or lactating.
  6. In the opinion of the investigator, EUS directed implantation posing undue study participant risk. This includes:

    • where previous EUS-FNA was considered technically too difficult to perform;
    • imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumour within the pancreas;
    • presence (or significant risk) of varices near to the target tumour. Note: The feasibility of implantation of the target tumour and assessment of risk can be conducted at any time between Screening Visit 1 and the implantation date. A study participant should be considered for withdrawal prior to and including at the time of OncoSil™ treatment, if any of the above risk features become apparent following subject screening and/or enrolment.
  7. History of malignancy, treated or untreated, within the past five years whether or not there is evidence of local recurrence or metastases, with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ.
  8. Evidence of radiographic invasion into stomach, duodenum or peritoneum (if not certain confirmation must be obtained prior to enrolment).
  9. A known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil™ components.
  10. Any other health condition that would preclude participation in the study in the judgment of the investigator.

Note: T1-T3 is determined as per The American Joint Committee on Cancer (AJCC) tumor/node/metastasis (TNM) classification and staging system for pancreatic cancer

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Belgium,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03003078
Other Study ID Numbers  ICMJE ONC01P03
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party OncoSil Medical Limited
Study Sponsor  ICMJE OncoSil Medical Limited
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Paul J Ross, MRCP MBBS Guy's and St Thomas' NHS Foundation Trust
PRS Account OncoSil Medical Limited
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP